君实生物(01877)公布一季度业绩 归母净亏损约2.83亿元 同比收窄47.92%
君实生物(01877)公布2024 年第一季度业绩，营业收入约3.81亿元，同比增长49.24%;归属于上市公司股东的净亏损约2.83亿元，同比收窄47.92%;基本每股亏损0.29元。
报告期内，公司营业收入增长主要来自商业化药品销售收入的增长，其中，核心产品特瑞普利单抗注射液(商品名：拓益®/LOQTORZI™，产品代号：JS001)于国内市场实现销售收入约3.07亿元，同比增长约 56.82%。与此同时，报告期内公司持续加强费用管控，优化资源配置，聚焦更有潜力的研发管线，与上年同期相比亏损减少。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.